Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celtaxsys Inc.
Insmed Goes Full Steam Ahead With Bronchiectasis Candidate
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.
Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA
Private start-up's acebilustat failed to improve lung function in Phase II, but the anti-inflammatory showed large numerical reductions in pulmonary exacerbations, which can be fatal.
Venture Funding Deals: BioNTech's Big Money Leads January Financings
BioNTech's $270m Series A round was the biggest start-up financing in January, but sizeable rounds also were raised by Centrexion ($67m), Eureka ($60m) and Pandion ($58m).
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.